Orgenesis (ORGS) Competitors $1.07 -0.23 (-17.69%) As of 03:45 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. INKT, PASG, SCYX, DYAI, ENLV, COEP, TPST, NRSN, CVKD, and CGTXShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include MiNK Therapeutics (INKT), Passage Bio (PASG), SCYNEXIS (SCYX), Dyadic International (DYAI), Enlivex Therapeutics (ENLV), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors MiNK Therapeutics Passage Bio SCYNEXIS Dyadic International Enlivex Therapeutics Coeptis Therapeutics Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics MiNK Therapeutics (NASDAQ:INKT) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings. Which has more risk and volatility, INKT or ORGS? MiNK Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Do analysts prefer INKT or ORGS? MiNK Therapeutics currently has a consensus target price of $37.50, suggesting a potential downside of 41.56%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe MiNK Therapeutics is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to INKT or ORGS? In the previous week, MiNK Therapeutics had 15 more articles in the media than Orgenesis. MarketBeat recorded 16 mentions for MiNK Therapeutics and 1 mentions for Orgenesis. MiNK Therapeutics' average media sentiment score of 0.43 beat Orgenesis' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Orgenesis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, INKT or ORGS? MiNK Therapeutics has higher earnings, but lower revenue than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.52-25.46Orgenesis$662K7.76-$55.36MN/AN/A Do insiders & institutionals have more ownership in INKT or ORGS? 2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is INKT or ORGS more profitable? MiNK Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -140.72% Orgenesis -3,827.81%N/A -130.18% SummaryMiNK Therapeutics beats Orgenesis on 8 of the 12 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.14M$839.61M$5.52B$9.07BDividend YieldN/A4.84%5.25%4.02%P/E RatioN/A1.3827.7220.26Price / Sales7.76241.37366.7878.98Price / CashN/A17.6937.4258.29Price / Book-0.166.528.045.49Net Income-$55.36M-$23.68M$3.18B$250.27M7 Day Performance-19.55%1.87%3.72%4.78%1 Month Performance-50.46%9.81%3.72%7.20%1 Year PerformanceN/A6.66%29.92%17.27% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesis1.7404 of 5 stars$1.07-17.7%N/AN/A$5.14M$662K0.00150INKTMiNK Therapeutics1.2466 of 5 stars$7.28+0.6%$37.50+415.5%-11.1%$28.82MN/A-2.8930Trending NewsGap UpTrading HaltedPASGPassage Bio2.7941 of 5 stars$0.43-6.1%$7.50+1,632.1%-51.6%$28.66MN/A-0.42130News CoverageStock SplitSCYXSCYNEXIS0.9732 of 5 stars$0.71-3.2%N/A-64.5%$28.54M$3.75M-1.2660Positive NewsDYAIDyadic International2.3428 of 5 stars$0.92-2.6%$6.00+555.4%-27.0%$28.28M$3.49M-4.587Gap DownENLVEnlivex Therapeutics2.9143 of 5 stars$1.21+2.5%$10.00+726.4%-4.3%$27.91MN/A-1.8370COEPCoeptis Therapeutics0.564 of 5 stars$7.73+2.5%N/A+68.4%$26.49M$62.87K-1.332Gap DownTPSTTempest Therapeutics2.4506 of 5 stars$7.08-0.7%$30.00+323.7%-73.7%$26.26MN/A-0.3920NRSNNeuroSense Therapeutics2.6891 of 5 stars$2.09+9.4%$14.00+569.9%+117.5%$26.10MN/A-3.8710News CoverageAnalyst ForecastCVKDCadrenal Therapeutics2.2885 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404CGTXCognition Therapeutics3.0511 of 5 stars$0.58+42.9%$2.83+389.5%-62.3%$25.11MN/A-0.7820News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies MiNK Therapeutics Alternatives Passage Bio Alternatives SCYNEXIS Alternatives Dyadic International Alternatives Enlivex Therapeutics Alternatives Coeptis Therapeutics Alternatives Tempest Therapeutics Alternatives NeuroSense Therapeutics Alternatives Cadrenal Therapeutics Alternatives Cognition Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
